DongKoo Bio & Pharma Co., Ltd. Logo

DongKoo Bio & Pharma Co., Ltd.

Pharma leader in dermatology, developing treatments, probiotics, and investing in biotech therapies.

006620 | KO

Overview

Corporate Details

ISIN(s):
KR7006620009
LEI:
Country:
South Korea
Address:
서울특별시 송파구 법원로 114, B동 14층, 송파구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

DongKoo Bio & Pharma Co., Ltd. is a pharmaceutical company founded in 1970 that engages in the research, development, manufacturing, and sale of medical products. The company is a recognized leader in the dermatology prescription market and also offers a portfolio of products including antihistamines, probiotics, and treatments for gum disease. Strategically expanding beyond traditional pharmaceuticals, the company pursues an 'Open Innovation' model to develop differentiated pipelines and invest in future technologies, with a focus on biotechnology and stem cell-based therapies. It operates with world-class research centers and GMP (Good Manufacturing Practice) certified facilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.1 MB
2025-07-02 00:00
M&A Activity
합병등종료보고서(합병)
Korean 16.5 KB
2025-06-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 125.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.0 MB
2025-04-30 00:00
M&A Activity
주요사항보고서(회사합병결정)
Korean 72.2 KB
2025-04-30 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 5.2 KB
2025-04-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 125.8 KB
2025-04-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 125.8 KB
2025-03-31 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.2 KB
2025-03-31 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 32.1 KB
2025-03-27 00:00
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
Korean 42.7 KB
2025-03-27 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 37.7 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 28.5 KB
2025-03-26 00:00
Remuneration Information
주식매수선택권부여에관한신고
Korean 17.3 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.3 KB

Automate Your Workflow. Get a real-time feed of all DongKoo Bio & Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DongKoo Bio & Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DongKoo Bio & Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

GENELUX Corp Logo
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
United States of America
GNLX
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea
109820
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America
GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea
011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America
GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway
GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France
GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America
GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye
GENIL
Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark
GMAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.